On Tuesday, BridgeBio Pharma Inc (NASDAQ: BBIO) opened higher 2.99% from the last session, before settling in for the closing price of $31.40. Price fluctuations for BBIO have ranged from $21.62 to $39.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 574.82% over the past five years. Company’s average yearly earnings per share was noted -31.31% at the time writing. With a float of $149.23 million, this company’s outstanding shares have now reached $190.04 million.
Let’s look at the performance matrix of the company that is accounted for 730 employees. In terms of profitability, gross margin is 97.67%, operating margin of -265.69%, and the pretax margin is -244.34%.
BridgeBio Pharma Inc (BBIO) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BridgeBio Pharma Inc is 21.54%, while institutional ownership is 76.14%. The most recent insider transaction that took place on Mar 06 ’25, was worth 419,500. In this transaction Director of this company sold 12,875 shares at a rate of $32.58, taking the stock ownership to the 1,764 shares. Before that another transaction happened on Mar 05 ’25, when Company’s 10% Owner sold 6,000,000 for $32.96, making the entire transaction worth $197,760,000. This insider now owns 19,260,971 shares in total.
BridgeBio Pharma Inc (BBIO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -31.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 41.46% during the next five years compared to -3.04% drop over the previous five years of trading.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Check out the current performance indicators for BridgeBio Pharma Inc (BBIO). In the past quarter, the stock posted a quick ratio of 4.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.85, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -2.77 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Inc (NASDAQ: BBIO) saw its 5-day average volume 3.63 million, a positive change from its year-to-date volume of 3.22 million. As of the previous 9 days, the stock’s Stochastic %D was 21.73%. Additionally, its Average True Range was 1.93.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 59.83%, which indicates a significant increase from 20.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.26% in the past 14 days, which was lower than the 61.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.05, while its 200-day Moving Average is $27.91. Nevertheless, the first resistance level for the watch stands at $32.88 in the near term. At $33.43, the stock is likely to face the second major resistance level. The third major resistance level sits at $34.20. If the price goes on to break the first support level at $31.57, it is likely to go to the next support level at $30.80. The third support level lies at $30.25 if the price breaches the second support level.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
There are currently 190,189K shares outstanding in the company with a market cap of 6.15 billion. Presently, the company’s annual sales total 221,900 K according to its annual income of -535,760 K. Last quarter, the company’s sales amounted to 5,880 K and its income totaled -265,050 K.
